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Circulating fibroblast growth factor 23 (FGF23) increases
renal phosphate excretion, decreases bone mineralization
and is markedly increased in hemodialysis patients. Bone
cells express fibroblast growth receptor 1, suggesting that
FGF23 could alter bone mineralization by means of a direct
effect on the skeleton and/or secondarily due to
hypophosphatemia. To distinguish between these
possibilities we measured serum concentrations of FGF23,
parathyroid hormone, phosphate, calcium, and markers of
bone remodeling, and assessed bone mineral density in 99
hemodialysis patients. FGF23 concentrations were increased
in all hemodialysis patients, even in those without
hyperphosphatemia, and positively correlated with serum
phosphate but not with parathyroid hormone. Hemodialysis
did not decrease the serum FGF23 concentration. We found
no significant correlation between serum FGF23 levels and
bone mineral density. Further analysis by gender or T-score
did not modify these results. Serum markers of bone
remodeling significantly correlated with parathyroid
hormone but not with FGF23 levels. The increase in serum
FGF23 concentration in hemodialysis patients cannot be
solely ascribed to hyperphosphatemia. Our study suggests
that the effects of FGF23 on bone mineralization are mainly
due to hypophosphatemia and not a direct effect on bone.
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Fibroblast growth factor 23 (FGF23) is a recently identified
molecule involved in the control of phosphate homeostasis
and calcitriol metabolism. This circulating 32 kDa peptide is
secreted by bone cells in response to hyperphosphatemia and
vitamin D therapy.1–3 In healthy subjects, plasma FGF23
concentration begins to rise 6–8 h after a high-phosphate
diet4 and is found constantly elevated in chronic hyperphos-
phatemic states.4,5 Administration of 1alpha,25-dihydroxy-
vitamin D3 (1,25OH2D3) in animals increases the expression
of FGF23 mRNA in bone cells and subsequently its serum
level.6,7 This effect is mediated through the binding of
1,25OH2D3 to the vitamin D-responsive elements present in
the promoter region of the FGF23 gene.8
FGF23 reduces serum phosphate levels at least by two
mechanisms: it decreases renal phosphate reabsorption by
lowering renal sodium–phosphate transporter (NPT)2a and
NPT2c expression and it diminishes plasma 1,25OH2D3
levels by inhibiting 1a-hydroxylase and by stimulating 24–25
hydroxylase activities.9–14 The reduction in 1,25OH2D3
results in the diminution of intestinal sodium phosphate
co-transporter NPT2b expression.9,15
Over-production of FGF23 in subjects with normal renal
function induces hypophosphatemia, low plasma 1,25OH2D3
levels, high serum parathyroid hormone (PTH) concentra-
tion, and severe bone demineralization.16–18 In contrast, the
decline of renal function in patients with chronic kidney
disease (CKD) is associated with a progressive augmentation
of circulating FGF23 concentration, which can be due to
serum phosphate accumulation and/or the decrease of the
renal clearance of FGF23.19–21 Once on dialysis therapy,
serum FGF23 levels are markedly increased and positively
correlated with serum phosphate levels.22 In addition, in
dialysis patients, high serum FGF23 concentration seems to
predict the occurrence of refractory secondary hyperpara-
thyroidism as reported by several groups.23,24
FGF23 might directly interfere with bone mineralization
independently of its hypophosphatemic effect and its
negative regulation of plasma 1,25OH2D3 levels. This is
highly suggested by the presence of the fibroblast growth
factor receptor type 1, which is one of the FGF23 putative
co-receptors, in osteoblast and osteoclast cells,25 and by the
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rapidity and severity of bone demineralization occurring after
administration of FGF23 in animal models, which cannot be
exclusively explained by the renal effects.26,27 If FGF23
modified bone mineralization by a direct action on bone
cells, this effect should persist or even be magnified in
hemodialysis patients with extremely high serum FGF23
levels and often markedly bone demineralization. Therefore,
the purpose of this study was to determine whether serum
FGF23 levels were associated with bone mineral content, as
assessed by dual-emission X-ray absorptiometry and bone
circulating biomarkers, in 99 patients on maintenance
hemodialysis.
RESULTS
Circulating FGF23 levels and correlation with serum
phosphate concentration
The main demographic and biological characteristics of the
99 hemodialysis patients participating in the study are
presented in Table 1. The distribution of pre-dialysis serum
phosphate concentration is shown in Figure 1a. Mean serum
phosphate concentration was above the normal range; however,
it was below the upper normal value (1.40 mM) in 24 patients
and below normal values (o0.85 mM) in 4 of them (Figure 1a
and b). Serum FGF23 concentrations were markedly increased
in all of the patients (mean7s.d.: 15 692717 496 RUml1;
range 1030–69 050 RU ml1). They positively correlated with
serum phosphate (Figure 1b) and calcium concentrations and
with serum calcium phosphate product (Figure 1c) but not with
serum PTH concentration (Figure 1d).
Effect of hemodialysis procedure on serum FGF23
concentration
To determine if the hemodialysis procedure decreased FGF23
levels, we measured serum FGF23 concentration before
starting and at the end of the hemodialysis session in 23
patients. As shown in Figure 2, serum FGF23 concentration
was significantly higher after the hemodialysis procedure
(pre-dialysis 16 241714 432; post-dialysis 20 791719 366).
This statistically significant difference still persisted after
correction for the hemoconcentration following the dialysis
ultrafiltration.28 FGF23 was undetectable in the dialysis fluid
exiting the dialyzer filter. Furthermore, pre-dialysis serum
FGF23 levels, in the whole population, did not correlate with
the dialysis efficacy as assessed by the percentage of reduction
in plasma urea after the dialysis and the Kt/V.
29
Correlation between serum FGF23 concentration and bone
mineralization
We report here the measurement of bone mineral density
(BMD) at four sites: lumbar spine, femoral neck, mid-radius,
and total body. The distributions of BMD expressed as
Z-scores at various sites in the present population of
hemodialysis patients were close to the normal distribution
(Figure 3). Z-score was lower than 2.5 in 5, 10, and 45% of
patients at femoral neck, lumbar and radius sites, respectively
(Figure 3a–c). We found no significant correlation between
serum FGF23 concentrations and BMD, either using absolute
values or T-scores or Z-scores at any site (Figure 4). The
analysis of the correlations by gender or by T-score did not
modify the results. We also considered the relation between
serum FGF23 and PTH concentrations and serum bone-
Table 1 | Patient characteristics
Age (years) 58.6714, range 21–87, median 60
Gender (M/F) (number) 69/30
Duration of dialysis (years) 6.876.9, range 1–29, median 4.0









Intact PTH (pg ml1) 3047290, range 3–1155
Plasma 25OHD3 (ng ml
1) 1378, range 4–47




Cross-laps (nmol l1) 18714, range 2–95
F, female; M, male; 25OHD3, hydroxyl vitamin D3; PTH, parathyroid hormone.
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Figure 1 | Serum phosphate and FGF23 concentrations in
hemodialysis patients. (a) Distribution of pre-dialysis serum
phosphate concentration in 99 patients on maintenance
hemodialysis. (b) Correlation between pre-dialysis serum phosphate
and FGF23 concentration expressed as log10 values (n¼ 99,
Po0.0001, r2¼ 0.259). (c) Correlation between serum calcium
phosphate ion product (Ca  P) and FGF23 concentration expressed
as log10 values (n¼ 99, Po0.0001, r2¼ 0.344). (d) Correlation
between pre-dialysis serum PTH and FGF23 concentration, both
expressed as log10 values (n¼ 99, P¼ 0.881, r2¼ 0.0003).
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specific alkaline phosphatase and cross-laps levels, two
circulating markers of bone remodeling. Both markers
significantly correlated with serum PTH concentra-
tion (Figure 5a and b) but not with serum FGF23 levels
(Figure 5c and d).
Correlation between serum C-terminal and intact FGF23
levels
To check that elevated FGF23 concentrations were not due to
the accumulation of C-terminal FGF23 by-products, we
measured serum intact FGF23 levels with a specific sandwich
ELISA (Kainos Laboratories Inc., Tokyo, Japan) in a
subgroup of 14 hemodialysis patients. The mean value was
822372084 pg ml1 (normal values o40 pg ml1). There
was an excellent positive correlation between serum C-
terminal and intact fibroblast growth factor (FGF23) (n¼ 14,
Po0.0001, r2¼ 0.804) (Figure 6).
DISCUSSION
In this study, we extend previous data demonstrating that
serum FGF23 levels are extremely elevated in all CKD
hemodialysis patients, including subjects with low and
normal pre-dialysis serum phosphate concentration, and
that those levels positively correlated with serum FGF23
concentrations. For the first time, we demonstrate that




















Figure 2 | Concentration of serum FGF23 concentration before
starting and at the end of the 4-h hemodialysis procedure in 23
























































Figure 3 | Distribution of BMD expressed as Z-scores at three
sites. BMD was measured by dual-emission X-ray absorptiometry
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Figure 4 | Correlation between serum FGF23 concentration,
expressed as log10 values, and BMD expressed as Z-scores at the
(a) femoral neck (n¼ 99, P¼ 0.239, r2¼ 0.01) and (b) lumbar
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Figure 5 | Correlation of circulating markers of bone remodeling
with serum PTH and FGF23 concentration. (a) Correlation between
serum cross-laps and serum PTH levels (n¼ 99, Po0.0001, r2¼ 0.349).
(b) Correlation between serum bone-specific alkaline phosphatase
(bAP) and serum PTH (n¼ 99, Po0.0001, r2¼ 0.190). (c) Correlation
between serum cross-laps and serum FGF23 levels (n¼ 99, P¼ 0.317,
r2¼ 0.014 ). (d) Correlation between bAP and FGF23 concentration
(n¼ 99, P¼ 0.392, r2¼ 0.01). All values are expressed as log10 because
of their known uneven distribution.
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serum FGF23 levels are not reduced by the dialysis procedure
in spite of the significant reduction of serum phosphate
concentration. Moreover, no correlation exists between
serum FGF23 levels and BMD at any of the four skeletal
sites explored, nor with several circulating biomarkers of
bone remodeling.
Serum FGF23 levels increase at the early stage of renal
diseases to compensate for the reduction of phosphate
excretion accompanying the decrease in glomerular filtration
rate. When these patients arrive at the end stage of renal
disease and are treated by hemodialysis, the increase in serum
FGF23 levels is more pronounced than what it is expected for
the degree of hyperphosphatemia. This is also illustrated by
our results showing that hyperphosphatemia cannot be the
explanation for the elevation of serum FGF23 levels in
hemodialysis patients with normal or low serum phosphate
concentrations. In these patients, serum FGF23 levels were
more than 10 times above the higher values observed in
healthy subjects and they only weakly correlated with serum
phosphate levels. Thus, a significant fraction of the elevated
serum FGF23 comes probably from its accumulation in the
organism because of the lack of its renal catabolism or its
renal clearance in these hemodialysis patients with practically
no residual renal function. In addition, despite its relative low
molecular weight of 32 kDa, FGF23 could not be removed by
the dialysis procedure. There was even a statistically
significant increase in serum FGF23 levels after the dialysis
procedure, which will need further investigation to under-
stand the mechanisms. The possibility that the kidney could
participate in FGF23 elimination is also suggested by the fact
that FGF23 was detected in the urine of one healthy
volunteer.19
In the hemodialysis population, the increase in serum
FGF23 concentration could also reflect an impaired regula-
tion of the synthesis and/or secretion of FGF23, similar to the
over-production of PTH observed in the case of autonomous
hyperparathyroidism. This is also suggested by the state of
tertiary hyperphosphatoninism recently described in hypo-
phosphatemic kidney transplanted patients.30 Although some
authors suggested that PTH stimulates the synthesis of
FGF23, our findings, showing no correlation between PTH
and serum FGF23 levels, argue against any important role of
PTH in the augmentation of serum FGF23 levels.
Vitamin D therapy could also be involved in the
augmentation of serum FGF23 concentrations; indeed,
administration of calcitriol in hemodialysis patients signi-
ficantly increases serum FGF23 concentration.2 However, we
did not observe any correlation between serum levels of
FGF23 and plasma levels of vitamin D and calcitriol or the
treatment by vitamin D analogs.
Bone demineralization and fractures are frequent in
hemodialysis patients. The mechanism of bone demineraliza-
tion in CKD patients is complex and not completely
understood.31–33 High PTH and low plasma 1,25(OH)2D3
levels certainly contribute to the pathogenesis of this disorder
but cannot completely explain it.34 High levels of serum
FGF23, which can predict the severity and resistance of
secondary hyperparathyroidism in dialysis patients, have now
been added to the list of these factors.23,24
Although high serum FGF23 concentrations cannot
induce hypophosphatemia in dialysis patients, it is unknown
whether the massive accumulation of FGF23 could directly
affect bone mineralization. We did not find any correlation
between serum FGF23 levels and BMD nor with bone
remodeling biomarkers in this study population. Our results
suggest that FGF23 may not have any direct effect on bone
mineralization in CKD dialysis patients. The decrease in bone
mineral content observed in subjects with normal renal
function is highly probable secondary to the renal phosphate
loss and hypophosphatemia.
In conclusion, in CKD patients on maintenance hemo-
dialysis, FGF23 accumulates in the circulation and correlates
with serum phosphate levels but is not associated with
decreased BMD.
MATERIALS AND METHODS
A total of 99 adult, Caucasian patients on maintenance hemodialysis
(30 females and 69 males) were included in this cross-sectional
study in accordance with the national guidelines for research on
human subjects. Mean duration of hemodialysis treatment was
6.876.9 years. All the patients were treated by conventional 4–5 h
hemodialysis, thrice a week, using hollow-fiber dialyzers, against a
dialysis bath containing 32–36 mmol l1 of bicarbonate,
0.85 mmol l1 of magnesium, 1.50–1.75 mmol l1 of calcium, and
2–3 mmol l1 of potassium. The underlying kidney diseases were
chronic glomerulonephritis (24), diabetes (15), chronic interstitial
nephritis (12), congenital nephropathy (7), polycystic kidney disease
(13), hypertensive nephrosclerosis (7), and other and unknown


















Figure 6 | Correlation between the logarithm of serum C-terminal
and intact FGF23 concentrations in a subgroup of 14
hemodialysis patients (n¼ 14, P&lt;0.0001, r2¼ 0.804). Serum
FGF23 concentrations were determined by two assays: the
Immutopics assay recognizes an epitope located in the C-terminal
part of FGF23 peptide and measures intact and C-terminal FGF23
peptides; the assay from Kainos measured only the intact (full-length)
FGF23 peptide.
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At the time of evaluation, none of the patients were receiving or
had received within the 3 months before the study estrogen,
calcitonin, bisphosphonate, or recombinant PTH. Two patients were
receiving less than 5 mg day1 of corticoids for b-2-microglobulin
amyloid arthropathy, 13 patients were receiving vitamin D
derivatives either orally or intravenously, and 46 patients were
receiving 0.5–3 g day1 of calcium carbonate. Seven patients have
had previous kidney transplantation. There was no clinical or
biological evidence for other bone diseases such as osteomalacia,
aluminum-related bone disease, and Paget’s disease. The main
clinical and biochemical features of patients are presented in Table 1.
BIOCHEMICAL ANALYSIS
Unless otherwise stated, all measurements were performed on
blood samples obtained just before starting hemodialysis
session and after a 12-h fast. Plasma calcium was determined
using atomic absorption spectrometry and plasma phos-
phorus using a Technicon Auto Analyzer. Plasma PTH
concentration was measured using a commercial radio-
immunometric assay for intact human PTH 1–84 (Elecsys,
from Roche Diagnostic, Meylan, France). The range of
normal values was between 15 and 65 pg ml1. Serum bone-
specific alkaline phosphatase was measured using a radio-
immunometric assay (Tandem-R, Ostase) provided by
Hybritech Europe SA, Belgium. The mean7s.d. value
obtained in normal adult individuals was 11.874.3 ng ml1
(normal range 4.0–25.0 ng ml1). Plasma vitamin D and
1,25(OH)2D3 were measured by radiocompetition assays.
Normal values for plasma vitamin D were 10–40 ng ml1 and
for 1,25(OH)2D3, 20–60 pg ml
1 for 1,25(OH)2D3. Serum
cross-laps levels were measured using an ELISA from
Osteometer, Biotech, Denmark. Normal values were
1.7470.74 nmol l1 in premenopausal women and
3.0171.55 nmol l1 in postmenopausal women.
Serum FGF23 levels were measured using an ELISA kit
from Immutopics (cterm FGF23, San Clemente, CA, USA).
Normal values ranged between 0 and 130 RU ml1. We also
measured serum intact FGF23 by a sandwich ELISA
purchased from Kainos Laboratories Inc. (Tokyo, Japan) as
described previously.35 This FGF23 assay utilizes specific
antibodies directed against the N- and C-terminal regions of
human FGF23 that allow the detection of only full-length
FGF23. Normal values for this assay ranged between 0 and
40 pg ml1.
BMD MEASUREMENTS
BMD was measured with a dual-energy X-ray absorptiometry
(Lunar DPX densitometer) from Lunar Corporation (Madi-
son, WI, USA). All the BMD measurements were performed
by the same experienced operator. The densitometer was
calibrated everyday with a standard phantom specimen. The
following sites were examined: the total body, lumbar spine
(vertebrae L2–L4), the femoral neck, trochanter, and mid-
radius. Scans were performed at the two forearms but only
the results at the non-dominant forearm were considered,
with the exception in the case of arteriovenous fistula
influence (three patients). BMD results are presented as
T-score. T-score is the number of standard deviations from
the mean of a healthy young adult population (20–40 years
old); it is used for the definition of osteopenia (T-score
between 1.0 and 2.5) and osteoporosis (T-score o2.5).
The reference values were obtained from a French normal
population aged between 20 and 89 years, issued from several
centers and provided by Lunar France.
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